Publications
Detailed Information
Comparison of intraoperative handling and wound healing between (NEOSORB® plus) and coated polyglactin 910 suture (NEOSORB®): a prospective, single-blind, randomized controlled trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Tae, Bum Sik | - |
dc.contributor.author | Park, Ju Hyun | - |
dc.contributor.author | Kim, Jung Kwon | - |
dc.contributor.author | Ku, Ja Hyeon | - |
dc.contributor.author | Kwak, Cheol | - |
dc.contributor.author | Kim, Hyeon Hoe | - |
dc.contributor.author | Jeong, Chang Wook | - |
dc.date.accessioned | 2018-10-24T08:06:41Z | - |
dc.date.available | 2018-10-24T17:07:54Z | - |
dc.date.issued | 2018-07-06 | - |
dc.identifier.citation | BMC Surgery, 18(1):45 | ko_KR |
dc.identifier.issn | 1471-2482 | - |
dc.identifier.uri | https://hdl.handle.net/10371/142937 | - |
dc.description.abstract | Background
Coated polyglactin 910 suture with chlorhexidine (NEOSORB® Plus) has recently been developed to imbue the parent suture with antibacterial activity against organisms that commonly cause surgical site infections (SSI). This prospective, single-blinded, randomized trial, was performed to compare the intraoperative handling and wound healing characteristics of NEOSORB® Plus with those of the traditional polyglactin 910 suture (NEOSORB®) in urologic surgery patients. Methods Patients (aged 19 to 80years, n = 100) were randomized in a 1:1 ratio for treatment with either NEOSORB® Plus or NEOSORB®, and stratified into an open surgery or a minimally invasive surgery group. The primary endpoint was the assessment of overall intraoperative handling of the sutures. Secondary endpoints included specific intraoperative handling measures and wound healing characteristics. Wound healing was assessed at one and 11days after surgery. Cumulative skin infection, seroma, and suture sinus events within 30days after surgery were also evaluated. Results A total of 96 patients were included, with 47 patients in the NEOSORB® Plus group and 49 patients in the NEOSORB® group. Scores for intraoperative handling were favorable and were not significantly different between the two suture groups. Wound healing characteristics were also comparable. The incidence of adverse events was 13.6%, although none were deemed attributable to the suture, and no difference was observed between the two groups. Conclusions NEOSORB® Plus is not inferior to traditional sutures in terms of intraoperative handling and wound healing, potentially making NEOSORB® Plus a beneficial alternative for patients at increased risk of SSI. Trial registration ClinicalTrials.gov: NCT02431039 . Trial registration date 14 August 2015. | ko_KR |
dc.description.sponsorship | This work was supported by Supporting Project to Test New Domestic Medical Devices in Hospitals funded by Ministry of Health and Welfare (MOHW), Korea Health Industry Development Institute (KHIDI) and Samyang Biopharmaceuticals Corp. No competing financial conflicts exist for any of
the authors. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | BioMed Central | ko_KR |
dc.subject | Surgical site infection | ko_KR |
dc.subject | Intraoperative handling | ko_KR |
dc.subject | Chlorhexidine acetate | ko_KR |
dc.subject | Polyglactin 910 suture | ko_KR |
dc.title | Comparison of intraoperative handling and wound healing between (NEOSORB® plus) and coated polyglactin 910 suture (NEOSORB®): a prospective, single-blind, randomized controlled trial | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 태범식 | - |
dc.contributor.AlternativeAuthor | 박주현 | - |
dc.contributor.AlternativeAuthor | 김정권 | - |
dc.contributor.AlternativeAuthor | 구자현 | - |
dc.contributor.AlternativeAuthor | 곽철 | - |
dc.contributor.AlternativeAuthor | 김현회 | - |
dc.contributor.AlternativeAuthor | 정창욱 | - |
dc.identifier.doi | 10.1186/s12893-018-0377-4 | - |
dc.language.rfc3066 | en | - |
dc.rights.holder | The Author(s). | - |
dc.date.updated | 2018-07-08T03:50:50Z | - |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.